Skip to content
BOLUS

Signal from the log

Enveda

311 M$ · Series D and later · United States · Biotech

Enveda cherche des médicaments dans les molécules naturelles. Sa plateforme PRISM lit des données de spectrométrie de masse, prédit la structure des molécules et classe celles qui ont un potentiel thérapeutique. Trois candidats sont en essai clinique, dont un en phase 2 dans la dermatite atopique.

Verified

Announced on , logged by the watch of 23 September 2026.

Operation
Funding round
Announced amount
311 M$
Stage
Series D and later
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by Catalio Capital Management , with Durable Capital Partners , ICONIQ , Lightspeed , Surveyor Capital , T. Rowe Price Investment Management , Digitalis Ventures , Alderline Group , Baillie Gifford , Premji Invest , FPV Ventures , True Ventures , Kinnevik , Dimension , Lifeforce Capital , Lux Capital

Provenance
Source biopharmadive,businesswire,divenewsletter,endpoints,pulse2,techcrunch-su
Logged on 23 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).